C9orf30_5730528L13Rik Inhibitors
Inhibitors targeting the functional activity of C9orf30 operate through various biochemical pathways, indirectly modulating its activity within the cell. By inhibiting essential kinases, the phosphorylation events crucial for the activation or stabilization of C9orf30 can be disrupted, leading to a decrease in its functional activity. For instance, broad-spectrum kinase inhibitors that prevent phosphorylation may alter cellular signaling cascades, which are vital for the proper functioning of C9orf30, particularly if its activity requires specific phosphorylated states. Furthermore, targeting key signaling pathways such as PI3K/Akt or MEK/ERK can have profound effects on proteins that are regulated through these pathways. The inhibition of these pathways could result in reduced phosphorylation and altered transcriptional regulation, thereby affecting proteins like C9orf30 that may rely on such signals for their activity.
Moreover, additional mechanisms of inhibition involve modulating cellular responses to stress and cytokines, as well as disrupting the normal processes of protein degradation and gene expression. For example, inhibitors that thwart the p38 MAPK can interfere with the cell's response to stress, which may in turn influence the activity of C9orf30. Proteasome inhibitors lead to the accumulation of proteins marked for degradation, which could result in the indirect inhibition of C9orf30, particularly if its regulation involves proteasomal pathways. Additionally, disruptions in cell cycle regulation through the inhibition of specific kinases involved in mitotic processes could also impact the activity of C9orf30. By affecting the transcriptional environment through the inhibition of histone deacetylases, the expression and function of C9orf30 can be indirectly suppressed, demonstrating the diverse array of mechanisms through which its activity can be inhibited.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that broadly targets protein kinases, which can indirectly inhibit C9orf30 by preventing phosphorylation events that may be necessary for its activation or stabilization within the cell. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of the PI3K/Akt pathway. Inhibition of this pathway could decrease the phosphorylation status of a variety of proteins, potentially including C9orf30, thereby affecting its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. By blocking this pathway, PD 98059 could alter transcriptional regulation by C9orf30 if it is dependent on MAPK signaling for its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor which could affect the activity of C9orf30 by modulating cellular growth and survival signals that may be essential for the proper functioning of C9orf30. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
An MEK inhibitor that prevents activation of the MAPK pathway. By inhibiting this pathway, U0126 could interfere with the signaling mechanisms that regulate the activity of C9orf30. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that could disrupt cellular responses to stress or cytokines, potentially affecting the activity of C9orf30 if it is involved in these pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which is part of another MAPK pathway. Inhibition of JNK signaling could indirectly affect the functional activity of C9orf30, especially if it plays a role in response to cellular stress. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor that could lead to decreased Akt signaling, potentially influencing the activity of C9orf30 if its function is related to this pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that can lead to the accumulation of proteins destined for degradation. This could indirectly inhibit C9orf30 if it is regulated by proteasomal degradation. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $56.00 $212.00 $764.00 | 24 | |
An MDM2 antagonist that leads to stabilization of p53. Increased p53 activity could indirectly inhibit C9orf30 if C9orf30 activity is negatively influenced by p53-dependent transcriptional regulation. | ||||||